Compare TWO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | GERN |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | 486 | 258 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 821.1M |
| IPO Year | N/A | N/A |
| Metric | TWO | GERN |
|---|---|---|
| Price | $12.52 | $1.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $12.56 | $2.17 |
| AVG Volume (30 Days) | 2.4M | ★ 14.2M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.84 | $1.04 |
| 52 Week High | $14.17 | $2.01 |
| Indicator | TWO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 32.94 |
| Support Level | $9.75 | $1.24 |
| Resistance Level | $12.70 | $1.29 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 56.90 | 10.42 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, residential mortgage loans, mortgage servicing rights, and commercial real estate. The majority of its investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. The company derives revenues mainly from its MSR and Agency RMBS portfolio, including servicing fee income, float income, and interest income, as well as mortgage loan origination activities established to support the MSR portfolio. Its investment portfolio is subject to market risks, mainly interest rate, basis, and prepayment risk. The majority of income is generated by available-for-sale securities.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.